The abstract is read at the publisher; the summary is JClub's.
FcγRIIIA-reporter assay measurements show serum immune complex bioactivity is significantly elevated across systemic autoimmune diseases, with SLE highest and linked to disease activity.
- Why it matters: Circulating immune complexes are thought to drive pathology via Fcγ receptors, but their functional bioactivity and relationship to activity across diseases are not well quantified.
- What they did: Serum IC bioactivity was quantified using an FcγRIIIA-reporter cell assay in healthy controls (n = 56), infectious controls (n = 12), and multiple systemic autoimmune cohorts (SLE n = 175; Sjögren n = 71; MCTD n = 22; myositis n = 73; systemic sclerosis n = 107; RA n = 51).
- The result: In SLE, IC bioactivity reflected disease activity with 81% sensitivity and 69% specificity; in low anti-double-stranded DNA patients, high IC bioactivity predicted higher risk of nephritis, arthritis, and skin involvement, and longitudinally more sensitively tracked flares than conventional markers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.